Round includes multiple global institutional investors including Flagship Pioneering, Pictet, Partners Investment, and M&G

轮包括多个全球机构投资者，包括旗舰开拓，Pictet，合作伙伴投资和M＆G

Financing will enable completion of clinical validation of Harbinger's first blood-based cancer screening product, further evidence-generation activities and continued organization scale-up ahead of anticipated 2025 product launch

融资将有助于完成Harbinger第一款基于血液的癌症筛查产品的临床验证，进一步的证据生成活动以及在预计2025年产品推出之前继续扩大组织规模

CAMBRIDGE, Mass., Sept. 28, 2023 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today that it raised $140 million in Series B funding. The financing round is comprised of the Company's founder, Flagship Pioneering, alongside new global institutional investors including Pictet, Partners Investment, and Catalyst, M&G Investments' purpose-led private assets strategy, among other investors.

马萨诸塞州剑桥市，2023年9月28日/PRNewswire/-开创新技术从根本上改变癌症筛查和检测的生物技术公司Harbinger Health今天宣布，它在B系列资金中筹集了1.4亿美元。融资轮由公司创始人，旗舰先驱，以及新的全球机构投资者组成，包括Pictet，Partners Investment和Catalyst，M＆G Investments的目标主导的私人资产战略以及其他投资者。

The new funds will be used to support the completion of Harbinger's Cancer ORigin Epigenetics-Harbinger Health (CORE-HH) 10,000-participant clinical study of its novel blood-based cancer screening platform; develop its two-tier testing model; expand its data science and commercial teams and capabilities; and initiate additional clinical studies in high-risk populations..

新资金将用于支持完成Harbinger癌症起源表观遗传学Harbinger Health（CORE-HH）10000参与者对其新型血液癌症筛查平台的临床研究；开发其两层测试模型；扩大其数据科学和商业团队和能力；并在高危人群中开展其他临床研究。。

Harbinger is developing a proprietary two-tier testing model with the goal of making cancer screening accessible on a global scale. Harbinger's product development strategy is designed to enable low-cost population testing to achieve broad affordability, improve Positive Predictive Value (PPV) to reduce the burden of false positives, and quantitative individual longitudinal monitoring to better guide clinical decision making if cancer is detected.

Harbinger正在开发专有的两层测试模型，目标是在全球范围内访问癌症筛查。Harbinger的产品开发策略旨在使低成本的人群测试能够实现广泛的负担能力，提高阳性预测值（PPV）以减少假阳性的负担，以及定量的个体纵向监测，以便在检测到癌症时更好地指导临床决策。

Harbinger's platform, HarbingerHx, leverages machine learning, proprietary insights into the molecular biology of cancer's origins, and growing datasets to develop insights that maximize clinical informativeness..

Harbinger的平台HarbingerHx利用机器学习，对癌症起源的分子生物学的专有见解以及不断增长的数据集来开发可最大化临床信息量的见解。。

The Company expects to launch its first product – a laboratory developed test (LDT) for the detection of early cancer – in 2025. The LDT, the HarbingerHx platform, and the Company's proprietary DNA library archiving technology together will make it possible to rapidly launch additional products over time, addressing specific disease types and population groups..

该公司预计将于2025年推出其第一款产品-用于检测早期癌症的实验室开发测试（LDT）。LDT，HarbingerHx平台和该公司专有的DNA库存档技术将使随着时间的推移快速推出其他产品成为可能，以解决特定的疾病类型和人群问题。。

'At Harbinger, our goal is to lead the way to a future where cancer screening is routine, affordable and accessible for everyone,' said Stephen Hahn, M.D., CEO of Harbinger Health. 'We have a unique opportunity to make cancer screening tools work better and work for more people through our biological and technical solutions.

“在Harbinger，我们的目标是引领未来，癌症筛查是常规的，负担得起的，每个人都可以访问，”Harbinger Health首席执行官Stephen Hahn说我们有一个独特的机会使癌症筛查工具更好地工作，并通过我们的生物和技术解决方案为更多人工作。

We are achieving this by combining machine learning with insights into the biology of cancer's origins and individual risk in order to provide actionable information to providers, enabling them to guide improved clinical decision making for their patients. This is where I see our greatest potential to reduce cancer mortality rates in our lifetimes.'.

我们正在通过将机器学习与癌症起源生物学和个人风险的见解相结合来实现这一目标，以便为提供者提供可操作的信息，使他们能够指导改善患者的临床决策。这就是我一生中降低癌症死亡率的最大潜力。

'Since its inception, Harbinger has built a platform that integrates our ability to understand the underlying biology of cancer with the ability to aggregate large datasets to fuel product development to solve some of the greatest challenges in the cancer screening field today,' said Douglas Cole, M.D., co-founder and chairman, Harbinger Health and managing partner, Flagship Pioneering.

“自成立以来，Harbinger已经建立了一个平台，将我们理解癌症潜在生物学的能力与聚合大型数据集以促进产品开发的能力相结合，以解决当今癌症筛查领域的一些最大挑战，”Douglas Cole说，医学博士，联合创始人兼主席，Harbinger Health和管理合作伙伴，旗舰先驱。

'This current financing will enable us to scale and advance a proprietary product model that optimizes for performance, accessibility, and cost and ultimately seeks to provide the right test for the right patient at the right time.'.

“目前的融资将使我们能够扩展和推进专有产品模型，优化性能，可访问性和成本，并最终寻求在正确的时间为正确的患者提供正确的测试。”。

Harbinger has raised approximately $190 million in total funding since its formation in 2020. This funding round comes on the heels of multiple business and clinical milestones for Harbinger as it continues the acceleration of its two-tier, multi-cancer platform, including multiple appointments to its executive leadership team and data presentations demonstrating the performance of Harbinger's platform..

自2020年成立以来，Harbinger的总资金约为1.9亿美元。这一轮资助是在先兆的多个业务和临床里程碑之后进行的，因为它继续加速其双层多癌症平台，包括对其执行领导团队的多次任命以及展示先兆平台性能的数据演示。。

About Harbinger Health

关于先兆健康

Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing low-cost, multi-cancer blood tests.

Harbinger Health开创了早期癌症的检测，并为癌症筛查，诊断和管理提供了基础性的新方法。该公司将人工智能的进步与癌症初期生物学的专有见解相结合，在癌症可见或有症状之前识别癌症，目的是开发低成本，多癌症的血液检查。

Harbinger envisions a future where, instead of keeping cancer from spreading, it could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems and societies. Harbinger was founded by Flagship Pioneering after three years of foundational research in its Labs unit and launched in 2020.

先兆设想了一个未来，在这个未来，癌症不是防止癌症扩散，而是可以防止癌症形成，使癌症诊断成为一个需要解决的常规健康问题，而不是担心生活改变事件会对人们，医疗系统和社会产生深远影响。Harbinger由Flagship开拓公司在其实验室部门进行了三年的基础研究，并于2020年启动。

Learn more about Harbinger by visiting www.harbinger-health.com or following us on Twitter (@harbingerhlth) and LinkedIn..

通过访问www.Harbinger-health.com或在Twitter（@harbingerhlth）和LinkedIn上关注我们，了解有关Harbinger的更多信息。。

Media Contactpress@harbinger-health.com

媒体Contactpress@harbinger-health.com

SOURCE Harbinger Health

来源Harbinger健康